Treatment with decitabine resulted in a similar survival and fewer adverse events compared with chemo in older patients with AML

Bookmark and Share
Published: 13 Jun 2022
Views: 26
Prof Michael Lübbert - Universitätsklinikum Freiburg, Freiburg, Germany

Prof Michael Lübbert presents data from the open-label randomised phase III study of the EORTC Leukemia group, GIMEMA, CELG, and GMDS- SG trial during a press conference at the EHA 2022 meeting.

The study compared the efficacy and safety of 10-day decitabine with conventional 3+7 IC as a treatment before HSCT in older (≥60 years) patients with newly diagnosed AML.

Read our news story here